| 货号 | 12919S |
| 反应种属 | Human/Mouse/Rat/Monkey |
| 来源宿主 | Rabbit |
| 应用 | W |
| 目标/特异性 | PSMB5 (D1H6B) Rabbit mAb recognizes endogenous levels of total PSMB5 protein. This antibody reacts with precursor and mature forms of PSMB5. This antibody does not cross-react with PSMB8. |
| 使用方法 | WB(1:1000) |
| 供应商 | CST |
| 背景 | The core particle performs three types of catalytic activities inside its chamber: chymotrypsin-like, trypsin-like, and caspase-like activities, which are provided by the constitutively expressed PSMB5 (β5/MB1/X/LMPX/Macropain epsilon chain), PSMB7 (β2/Z/Macropain chain Z) and PSMB6 (β1/Y/LMPY/Macropain delta chain) subunits, respectively. These catalytic subunits belong to the amino-terminal nucleophile (Ntn) hydrolase family and are characterized by a single-residue active site. The catalytic β-subunits are synthesized with amino-terminal propeptides, which are removed at the final step of proteasome biogenesis to expose the catalytic threonine residues (3). In immune cells involved in antigen presentation, the constitutively expressed PSMB6, PSMB7, and PSMB5 subunits are replaced by three highly homologous induced β-subunits: PSMB9 (β1i/LMP2/RING12), PSMB10 (β2i/MECL-1/LMP10) and PSMB8 (β5i/LMP7/RING10), respectively, to form the immunoproteasome (4,5). PSMB5 is downregulated at the protein level by IFN-γ and replaced by PSMB8 in order to remodel the proteolytic specificity of the proteasome for more appropriate immunological processing of endogenous antigens (6-8). PSMB5 is also one of the predominant targets of bortezomib, an inhibitor of the chymotrypsin-like activity of the proteasome (9).核心颗粒由它内部的三种催化活性类型构成：糜蛋白酶样、胰蛋白酶样和半胱天冬酶样活性，由组成性表达的PSMB5 (β5/MB1/X/LMPX/Macropain epsilon链), PSMB7 (β2/Z/Macropain 链 Z)和PSMB6 (β1/Y/LMPY/Macropain delta 链)亚基分别组成。这些催化亚基属于N-末端亲核(Ntn)水解酶家族，并有标志性的单一残基活化位点。每一种蛋白水解亚基的N-末端苏氨酸提供催化的亲核体（在侧链上）和主要的质子接受体（在主要的链N-末端）。β-催化亚基由N-末端前肽合成，通过限制性蛋白水解暴露于催化的苏氨酸残基，在蛋白酶体发生的最后被去除(3)。免疫应答的免疫细胞中，组成性地表达PSMB6、PSMB、PSMB5亚基分别被3种高度同源的诱导β-亚基：PSMB9 (β1i/LMP2/RING12), PSMB10 (β2i/MECL-1/LMP10) 和 PSMB8 (β5i/LMP7/RING10)取代，从而形成免疫蛋白酶体(4,5)。PSMB5由IFN-γ在蛋白水平下调，并由PSMB8代替，为了改变蛋白酶体的蛋白水解特异性，从而为内源性抗原提供适当的免疫处理(6-8)。PSMB5也是bortezomib的主要靶点，bortezomib是一种糜蛋白样蛋白酶体活性的抑制因子(9)。 |
| 存放说明 | -20C |
| 计算分子量 | 22, 28 |
Western blot analysis of extracts from various cell lines using PSMB5 (D1H6B) Rabbit mAb.Western blot检测多种细胞提取物，使用的抗体是PSMB5 (D1H6B) Rabbit mAb。 | |
Western blot analysis of extracts from 293T cells, mock transfected (-) or transfected with constructs expressing Myc/DDK-tagged full-length human PSMB5 (hPSMB5-Myc/DDK; +) or Myc/DDK-tagged full-length human PSMB8 (hPSMB8-Myc/DDK; +), using PSMB5 (D1H6B) Rabbit mAb (upper) and DYKDDDDK Tag Antibody #2368 (lower).Western blot检测293T细胞提取物，未转染 (-) 或转染有表达Myc/DDK标签人全长PSMB5 (hPSMB5-Myc/DDK; +) 和Myc/DDK标签人全长PSMB8 (hPSMB8-Myc/DDK; +)，使用的抗体是PSMB5 (D1H6B) Rabbit mAb (上图)和DYKDDDDK Tag Antibody #2368 (下图)。 | |
Western blot analysis of extracts from HeLa cells, untreated (-) or treated with Human Interferon-γ (hIFN-γ) #8901 (100 ng/ml, 72 hr; +), using PSMB5 (D1H6B) Rabbit mAb (upper) or GAPDH (D16H11) XP® Rabbit mAb #5174 (lower).Western blot检测HeLa细胞提取物，未处理（-）或人干扰素γ (hIFN-γ) #8901处理(100 ng/ml, 72小时；+)，使用的抗体是PSMB5 (D1H6B) Rabbit mAb (上图) 或GAPDH (D16H11) XP® Rabbit mAb #5174 (下图)。 |
